Stock Research: Roche

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Roche

VTX:ROG CH0012032048
24
  • Value
    63
  • Growth
    44
  • Safety
    Safety
    22
  • Combined
    22
  • Sentiment
    49
  • 360° View
    360° View
    24
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Roche Holding AG is a healthcare company focused on pharmaceuticals and diagnostics. The company operates in the pharmaceuticals and diagnostics industries with business segments in Pharmaceuticals (Roche Pharmaceuticals and Chugai) and Diagnostics (Diabetes Care, Molecular Diagnostics, Professional Diagnostics, and Tissue Diagnostics). The company develops medicines for oncology, immunology, infectious diseases, ophthalmology, and neuroscience. In the last fiscal year, the company had a market cap of $258,542 million, profits of $49,371 million, and revenue of $66,683 million, with 103249 employees.

more
Index
SPI
SPI
SMI
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 27-Feb-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
63 51 61 50
Growth
44 55 17 31
Safety
Safety
22 14 30 45
Sentiment
49 79 64 14
360° View
360° View
24 45 30 24
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
17 24 26 55
Opinions Change
72 75 54 16
Pro Holdings
n/a 92 63 30
Market Pulse
39 67 79 39
Sentiment
49 79 64 14
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
63 51 61 50
Growth
44 55 17 31
Safety Safety
22 14 30 45
Combined
22 22 14 30
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
52 31 39 36
Price vs. Earnings (P/E)
42 56 70 58
Price vs. Book (P/B)
22 10 12 10
Dividend Yield
85 87 90 86
Value
63 51 61 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
34 34 25 12
Profit Growth
64 51 29 37
Capital Growth
45 51 46 39
Stock Returns
49 80 36 76
Growth
44 55 17 31
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
17 12 20 43
Refinancing
35 22 21 14
Liquidity
56 63 73 74
Safety Safety
22 14 30 45

Similar Stocks

Discover high‑ranked alternatives to Roche and broaden your portfolio horizons.

Grifols

MCE:GRF
Country: Spain
Industry: Biotechnology
Size: X-Large
Full Stock Analysis

Zehnder Group

SWX:ZEHN
Country: Switzerland
Industry: Building Products
Size: Medium
Full Stock Analysis

Phoenix Mecano

SWX:PMN
Country: Switzerland
Industry: Electr. Components & Equipment
Size: Medium
Full Stock Analysis

Richter Gedeon

BUD:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a highly risky stock investment proposition as all consolidated ranks are below-average. There are no compelling arguments to support this stock based on current information. It is not recommended for any investor profile. However, performance does change, so it could we worth keepin on a watchlist.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: